MusthInsider

Latest On Spero Therapeutics, Inc (SPRO):

Updated on: March 18, 2021

Date/Time	Type	Description	Signal
2023-05-12 00:52 EST	News	Spero Therapeutics GAAP EPS of -$0.25 beats by $0.08, revenue of $2.07M beats by $0.8M	N/A
2023-05-12 00:51 EST	News	Spero Therapeutics, Inc. (SPRO) Q1 2023 Earnings Call Transcript	N/A
2023-05-10 20:41 EST	News	Spero Therapeutics Q1 2023 Earnings Preview	N/A
2023-04-22 00:37 EST	News	Spero Therapeutics: Massive Partnership Deal Still Not Properly Valued By The Market	N/A
2023-03-31 10:33 EST	News	Spero Therapeutics GAAP EPS of $0.55 beats by $0.51, revenue of $47.44M beats by $24.57M	N/A
2023-03-31 10:33 EST	News	Spero Therapeutics, Inc. (SPRO) Q4 2022 Earnings Call Transcript	N/A
2023-03-13 03:53 EST	News	Spero Therapeutics Q4 2022 Earnings Preview	N/A
2022-11-15 07:59 EST	News	Spero Therapeutics GAAP EPS of -$0.33 misses by $0.03, revenue of $2M misses by $3.42M	N/A
2022-11-15 07:59 EST	News	Spero Therapeutics, Inc. (SPRO) Q3 2022 Earnings Call Transcript	N/A
2022-11-12 11:25 EST	News	Spero Therapeutics Q3 2022 Earnings Preview	N/A
2022-10-03 16:29 EST	News	Spero Therapeutics: The GlaxoSmithKline-Deal Changes Everything And Protects Shareholder Value	N/A
2022-09-22 06:48 EST	News	Spero stock soars 79% as GSK to pick stake under license deal for UTI antibiotic	N/A
2022-09-15 22:23 EST	News	Spero Therapeutics appoints Kamal Hamed MD CMO	N/A
2022-09-07 07:24 EST	News	Spero jumps 64% as FDA clarifies future regulatory path for UTI candidate	N/A
2022-08-12 08:06 EST	News	Spero Therapeutics, Inc. (SPRO) CEO Ankit Mahadevia on Q2 2022 Results - Earnings Call Transcript	N/A
2022-08-10 23:40 EST	News	Spero Therapeutics GAAP EPS of -$0.87, revenue of $1.99M	N/A
2022-06-28 10:10 EST	News	FDA rejects Spero's application seeking approval of its urinary tract infection tablets	N/A
2022-05-17 17:21 EST	News	Spero Therapeutics, Inc. (SPRO) CEO Ankit Mahadevia on Q1 2022 Results - Earnings Call Transcript	N/A
2022-05-16 19:16 EST	News	Spero Therapeutics GAAP EPS of -$1.01 misses by $0.08, revenue of $2.07M beats by $0.14M	N/A
2022-05-16 02:24 EST	News	Spero Therapeutics Q1 2022 Earnings Preview	N/A
2022-05-04 12:34 EST	News	Spero downgraded at Cowen after regulatory setback to lead asset	N/A
2022-05-03 20:42 EST	News	Spero stock crashes 70% on potential FDA rejection of uti drug tebipenem; to cut workforce by ~75%	N/A
2022-04-18 20:38 EST	News	Spero Therapeutics stock dips after PT cut to $37 at H.C. Wainwright on pending approval of tebipenem HBr	N/A
2022-04-01 12:23 EST	News	Spero Therapeutics, Inc. (SPRO) CEO Ankit Mahadevia on Q4 2021 Results - Earnings Call Transcript	N/A
2022-04-01 12:23 EST	News	Spero Therapeutics slips after FDA feedback on antibacterial therapy	N/A
2022-03-31 18:25 EST	News	Spero Therapeutics GAAP EPS of -$0.90 misses by $0.15, revenue of $2.74M misses by $2.21M	N/A
2022-02-17 03:46 EST	News	Spero Therapeutics antibiotic SPR206 shows promise in phase 1 trial	N/A
2022-01-19 17:56 EST	News	Spero granted up to $12.9M by BARDA to develop urinary tract infection drug for children	N/A
2022-01-04 18:28 EST	News	FDA lifts clinical hold on Spero's mid-stage SPR720 trial in nontuberculous mycobacterial	N/A
2022-01-03 09:48 EST	News	Spero gets FDA priority review for oral tebipenem HBr to treat urinary tract infections	N/A
2021-11-11 13:22 EST	News	Spero Therapeutics EPS misses by $0.04, misses on revenue	N/A
2021-11-11 13:22 EST	News	Spero Therapeutics, Inc. (SPRO) CEO Ankit Mahadevia on Q3 2021 Results - Earnings Call Transcript	N/A
2021-11-10 16:04 EST	News	Spero Therapeutics Q3 2021 Earnings Preview	N/A
2021-10-29 05:35 EST	News	Spero Therapeutics submits tebipenem NDA for treatment of complicated urinary tract infections	N/A
2021-10-15 20:49 EST	News	Sizing Up Spero Therapeutics	N/A
2021-10-01 21:44 EST	News	Spero Therapeutics shares fall on Oppenheimer downgrade	N/A
2021-08-17 01:01 EST	News	Spero Therapeutics, Inc. 2021 Q2 - Results - Earnings Call Presentation	N/A
2021-08-08 01:05 EST	News	Spero Therapeutics, Inc. (SPRO) CEO Ankit Mahadevia on Q2 2021 Results - Earnings Call Transcript	N/A
2021-08-06 10:52 EST	News	Spero Therapeutics EPS beats by $0.12, beats on revenue	N/A
2021-07-22 01:45 EST	News	Spero Therapeutics initiates two early-stage trials for SPR206	N/A
2021-07-22 01:29 EST	News	Spero Therapeutics stock gains on $40M equity investment from Pfizer and licensing agreement for SPR206	N/A
2021-07-22 01:15 EST	News	Spero Therapeutics (SPRO) Presents At Ladenburg Thalmann Healthcare Conference - Slideshow	N/A
2021-05-06 19:23 EST	News	Spero Therapeutics EPS misses by $0.01, beats on revenue	N/A
2021-03-24 06:25 EST	News	Spero Therapeutics (SPRO) Presents At Oppenheimer 31st Annual Healthcare Conference - Slideshow	N/A
2021-03-16 22:05 EST	Analyst Rating	The Analyst Target Price has increased from $32.88 to $33.	Buy
2021-03-12 11:34 EST	News	Spero Therapeutics EPS beats by $0.06, misses on revenue	N/A
2021-03-12 11:34 EST	News	Spero Therapeutics' (SPRO) CEO Ankit Mahadevia on Q4 2020 Results - Earnings Call Transcript	N/A
2021-03-12 08:35 EST	Financials	Company financials have been released.	Neutral
2021-03-12 04:43 EST	Earnings Estimate	An EPS average of -$3.81 is estimated for the 2022 year.	Sell
2021-03-12 04:43 EST	Earnings Estimate	An EPS average of -$0.86 is estimated for the quarter ending on June 30, 2021.	Sell

About Spero Therapeutics, Inc (SPRO):

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. Its product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, an oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary disease. Spero Therapeutics, Inc. has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; license agreement with Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; collaboration agreement with Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis; and license agreement with Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

See Advanced Chart

General

Name Spero Therapeutics, Inc
Symbol SPRO
Type Common Stock
Exchange NASDAQ
Currency USD
Country USA
SectorHealthcare
IndustryBiotechnology
Full Time Employees 89
Fiscal Year EndDecember
IPO Date2017-11-02
Gic SectorHealth Care
Gic GroupPharmaceuticals, Biotechnology & Life Sciences
Gic IndustryBiotechnology
Gic SubIndustryBiotechnology
Web URLhttp://sperotherapeutics.com

Valuation

Price/Sales (Trailing 12 Mt.) 40.38
Price/Book (Most Recent Quarter) 3.76
Enterprise Value Revenue 40.46

Financials

Most Recent Quarter 2020-12-31
Current Year EPS Estimate -$2.82
Next Year EPS Estimate -$3.02
Next Quarter EPS Estimate -$0.80
Operating Margin -848%
Return on Assets -38%
Return on Equity -76%
Revenue 9.33 million
Earnings Per Share -$2.24
Revenue Per Share $0.42
Gross Profit -57673000
Quarterly Earnings Growth -47.5%

Highlights

Market Capitalization 485.05 million
EBITDA -40775000
Analyst Target Price $33
Book Value Per Share $4.51

Share Statistics

Shares Outstanding 29.5 million
Shares Float 21.6 million
% Held by Insiders 1081%
% Held by Institutions 60.98%
Shares Short 2.2 million
Shares Short Prior Month 2.24 million
Short Ratio 6.89
Short % of Float 9%
Short % of Shares Outstanding 8%

Technicals

Beta 1.67
52 Week High $23.64
52 Week Low $5.51
50 Day Moving Average 18.65
200 Day Moving Average 15.69

Dividends

Dividend Date N/A
ExDividend Date N/A
Dividend Yield 0%

Spero Therapeutics, Inc (SPRO) Dividend Calendar:

Ex-Dividend Date	Payment Date	Record Date	Declared Date	Amount

Spero Therapeutics, Inc (SPRO) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.

Quarter Date	Report Date	Actual Revenue	Reported EPS	EPS Estimate	Deviation from Estimate
2020-12-31	2021-03-11	$1.91 million	-$0.68	-$0.74	8.36%
2020-09-30	2020-11-05	$N/A	-$0.86	-$0.89	2.93%
2020-06-30	2020-08-06	$N/A	-$0.85	-$1.13	24.78%
2020-03-31	2020-05-08	$N/A	-$1.22	-$1.38	11.43%
2019-12-31	2020-03-16	$3.63 million	-$1.36	-$1.08	-25.46%
2019-09-30	2019-11-04	$4.64 million	-$0.95	-$0.85	-12.2%
2019-06-30	2019-08-08	$2.16 million	-$0.74	-$0.86	13.95%
2019-03-31	2019-05-09	$7.72 million	-$0.29	-$0.77	62.34%
2018-12-31	2019-03-14	$1.69 million	-$0.60	-$0.75	19.57%
2018-09-30	2018-11-08	$658000	-$0.60	-$0.63	4.76%
2018-06-30	2018-08-09	$463000	-$0.69	-$0.78	10.97%
2018-03-31	2018-05-10	$1.15 million	-$0.74	-$1.20	38.33%
2017-09-30	2017-12-14	$597000	-$36.02	-$35.07	-2.72%

Spero Therapeutics, Inc (SPRO) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:

Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares

Cash Flow:

Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures

Balance Sheet:

Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

Spero Therapeutics, Inc (SPRO) Chart:

Spero Therapeutics, Inc (SPRO) News:

Below you will find a list of latest news for Spero Therapeutics, Inc (SPRO) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Spero Therapeutics, Inc (SPRO) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date	Strike	Last Price	Type	Volume	Open Interest	Implied Volatility	In The Money
2024-04-19	1	0.65	CALL	0	37	0	TRUE
2024-04-19	2	0.05	CALL	0	1594	0	FALSE
2024-04-19	3	0.05	CALL	0	15	0	FALSE
2024-04-19	4	0.35	CALL	0	10	0	FALSE
2024-04-19	1	0.05	PUT	0	20	0	FALSE
2024-04-19	2	0.5	PUT	0	1	273	TRUE
2024-04-19	3	0	PUT	0	0	1116.24	TRUE
2024-04-19	4	0	PUT	0	0	1154.56	TRUE
2024-05-17	2.5	0.2	CALL	0	17	0	FALSE
2024-05-17	5	0	CALL	0	0	0	FALSE
2024-05-17	7.5	0	CALL	0	0	0	FALSE
2024-05-17	2.5	0	PUT	0	0	133.57	TRUE
2024-05-17	5	0	PUT	0	0	579.07	TRUE
2024-05-17	7.5	0	PUT	0	0	707.17	TRUE
2024-07-19	2.5	0.1	CALL	19	383	103.97	FALSE
2024-07-19	5	0.14	CALL	0	4	0	FALSE
2024-07-19	7.5	0	CALL	0	0	0	FALSE
2024-07-19	2.5	0.9	PUT	0	10	291.79	TRUE
2024-07-19	5	0	PUT	0	0	341.98	TRUE
2024-07-19	7.5	0	PUT	0	0	419.88	TRUE
2024-10-18	2.5	0.45	CALL	0	12	0	FALSE
2024-10-18	5	0	CALL	0	0	0	FALSE
2024-10-18	7.5	0	CALL	0	0	0	FALSE
2024-10-18	2.5	0	PUT	0	0	117.91	TRUE
2024-10-18	5	0	PUT	0	0	252.44	TRUE
2024-10-18	7.5	0	PUT	0	0	189	TRUE

Latest SPRO Trades:

Date	Shares	Price
Jun 13, 2022 7:58 PM EST	9	$1.015
Jun 13, 2022 7:58 PM EST	38	$1.015
Jun 13, 2022 7:58 PM EST	15	$1.015
Jun 13, 2022 7:58 PM EST	26	$1.015
Jun 13, 2022 7:59 PM EST	100	$1.02

Spero Therapeutics, Inc (SPRO) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date	Form Type	Form Name	Link
2020-06-29	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1701108/000120919120039352/0001209191-20-039352-index.htm
2019-02-13	SC 13G/A	Statement of acquisition of beneficial ownership by individuals	https://www.sec.gov/Archives/edgar/data/1701108/000031506619001334/0000315066-19-001334-index.htm
2018-06-06	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1701108/000089924318015325/0000899243-18-015325-index.htm
2018-06-06	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1701108/000089924318015326/0000899243-18-015326-index.htm
2018-06-06	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1701108/000089924318015327/0000899243-18-015327-index.htm
2018-06-06	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1701108/000089924318015328/0000899243-18-015328-index.htm
2018-06-06	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1701108/000089924318015329/0000899243-18-015329-index.htm
2018-06-06	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1701108/000089924318015330/0000899243-18-015330-index.htm
2018-07-06	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1701108/000089924318019566/0000899243-18-019566-index.htm
2018-07-06	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1701108/000089924318019567/0000899243-18-019567-index.htm
2018-07-06	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1701108/000089924318019568/0000899243-18-019568-index.htm
2018-09-21	3	Initial statement of beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1701108/000089924318025017/0000899243-18-025017-index.htm
2018-09-21	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1701108/000089924318025024/0000899243-18-025024-index.htm
2019-01-02	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1701108/000089924319000175/0000899243-19-000175-index.htm
2019-01-02	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1701108/000089924319000178/0000899243-19-000178-index.htm
2019-01-02	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1701108/000089924319000179/0000899243-19-000179-index.htm
2019-01-02	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1701108/000089924319000181/0000899243-19-000181-index.htm
2019-01-02	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1701108/000089924319000183/0000899243-19-000183-index.htm
2019-03-19	3	Initial statement of beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1701108/000089924319008360/0000899243-19-008360-index.htm
2019-03-29	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1701108/000089924319009318/0000899243-19-009318-index.htm
2019-06-05	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1701108/000089924319015663/0000899243-19-015663-index.htm
2019-06-05	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1701108/000089924319015665/0000899243-19-015665-index.htm
2019-06-05	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1701108/000089924319015667/0000899243-19-015667-index.htm
2019-06-05	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1701108/000089924319015668/0000899243-19-015668-index.htm
2019-06-05	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1701108/000089924319015672/0000899243-19-015672-index.htm
2019-06-05	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1701108/000089924319015673/0000899243-19-015673-index.htm
2019-11-08	3	Initial statement of beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1701108/000089924319026993/0000899243-19-026993-index.htm
2020-01-06	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1701108/000089924320000625/0000899243-20-000625-index.htm
2020-01-06	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1701108/000089924320000628/0000899243-20-000628-index.htm
2020-01-06	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1701108/000089924320000629/0000899243-20-000629-index.htm
2020-01-06	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1701108/000089924320000631/0000899243-20-000631-index.htm
2020-01-13	3	Initial statement of beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1701108/000089924320001061/0000899243-20-001061-index.htm
2020-02-03	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1701108/000089924320002604/0000899243-20-002604-index.htm
2020-02-03	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1701108/000089924320002616/0000899243-20-002616-index.htm
2020-02-03	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1701108/000089924320002617/0000899243-20-002617-index.htm
2020-02-03	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1701108/000089924320002618/0000899243-20-002618-index.htm
2020-04-23	3	Initial statement of beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1701108/000089924320011244/0000899243-20-011244-index.htm
2020-06-23	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1701108/000089924320017496/0000899243-20-017496-index.htm
2020-07-09	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1701108/000089924320018847/0000899243-20-018847-index.htm
2020-09-10	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1701108/000089924320024865/0000899243-20-024865-index.htm
2020-10-15	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1701108/000089924320028430/0000899243-20-028430-index.htm
2020-10-27	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1701108/000089924320029326/0000899243-20-029326-index.htm
2020-10-27	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1701108/000089924320029327/0000899243-20-029327-index.htm
2020-10-27	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1701108/000089924320029328/0000899243-20-029328-index.htm
2020-10-27	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1701108/000089924320029329/0000899243-20-029329-index.htm
2020-10-27	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1701108/000089924320029333/0000899243-20-029333-index.htm
2020-10-27	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1701108/000089924320029334/0000899243-20-029334-index.htm
2020-10-27	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1701108/000089924320029337/0000899243-20-029337-index.htm
2020-10-27	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1701108/000089924320029338/0000899243-20-029338-index.htm
2020-11-05	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1701108/000089924320030490/0000899243-20-030490-index.htm
2018-07-17	SC 13D/A	General statement of acquisition of beneficial ownership	https://www.sec.gov/Archives/edgar/data/1701108/000090342318000399/0000903423-18-000399-index.htm
2018-07-17	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1701108/000090342318000400/0000903423-18-000400-index.htm
2018-09-19	SC 13D/A	General statement of acquisition of beneficial ownership	https://www.sec.gov/Archives/edgar/data/1701108/000090342318000513/0000903423-18-000513-index.htm
2019-02-14	SC 13G/A	Statement of acquisition of beneficial ownership by individuals	https://www.sec.gov/Archives/edgar/data/1701108/000092189519000484/0000921895-19-000484-index.htm
2018-05-25	DRS	Draft Registration Statement	https://www.sec.gov/Archives/edgar/data/1701108/000095012318005976/0000950123-18-005976-index.htm
2019-02-08	SC 13G/A	Statement of acquisition of beneficial ownership by individuals	https://www.sec.gov/Archives/edgar/data/1701108/000110465919006432/0001104659-19-006432-index.htm
2020-02-04	SC 13G/A	Statement of acquisition of beneficial ownership by individuals	https://www.sec.gov/Archives/edgar/data/1701108/000110465920010526/0001104659-20-010526-index.htm
2019-02-14	SC 13G/A	Statement of acquisition of beneficial ownership by individuals	https://www.sec.gov/Archives/edgar/data/1701108/000114420419008281/0001144204-19-008281-index.htm
2018-04-02	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1701108/000119312518104993/0001193125-18-104993-index.htm
2018-04-27	DEF 14A	Other definitive proxy statements	https://www.sec.gov/Archives/edgar/data/1701108/000119312518136751/0001193125-18-136751-index.htm
2018-05-10	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1701108/000119312518159225/0001193125-18-159225-index.htm
2018-06-08	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1701108/000119312518188029/0001193125-18-188029-index.htm
2018-07-09	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1701108/000119312518214220/0001193125-18-214220-index.htm
2018-07-09	S-1	General form for registration of securities under the Securities Act of 1933	https://www.sec.gov/Archives/edgar/data/1701108/000119312518214717/0001193125-18-214717-index.htm
2018-07-09	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1701108/000119312518214735/0001193125-18-214735-index.htm
2018-07-11	S-1/A	General form for registration of securities under the Securities Act of 1933	https://www.sec.gov/Archives/edgar/data/1701108/000119312518216210/0001193125-18-216210-index.htm
2018-07-13	424B4	Prospectus [Rule 424(b)(4)]	https://www.sec.gov/Archives/edgar/data/1701108/000119312518217909/0001193125-18-217909-index.htm
2018-07-16	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1701108/000119312518218281/0001193125-18-218281-index.htm
2018-07-17	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1701108/000119312518219722/0001193125-18-219722-index.htm
2018-08-09	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1701108/000119312518244366/0001193125-18-244366-index.htm
2018-08-14	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1701108/000119312518247901/0001193125-18-247901-index.htm
2018-09-27	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1701108/000119312518285631/0001193125-18-285631-index.htm
2018-11-08	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1701108/000119312518322565/0001193125-18-322565-index.htm
2018-11-13	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1701108/000119312518324949/0001193125-18-324949-index.htm
2018-11-16	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1701108/000119312518328530/0001193125-18-328530-index.htm
2018-12-03	S-3	Registration statement under Securities Act of 1933	https://www.sec.gov/Archives/edgar/data/1701108/000119312518341227/0001193125-18-341227-index.htm
2018-12-07	CORRESP	Correspondence	https://www.sec.gov/Archives/edgar/data/1701108/000119312518344890/0001193125-18-344890-index.htm
2019-01-07	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1701108/000119312519003882/0001193125-19-003882-index.htm
2019-03-14	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1701108/000119312519074792/0001193125-19-074792-index.htm
2019-03-14	S-8	Securities to be offered to employees in employee benefit plans	https://www.sec.gov/Archives/edgar/data/1701108/000119312519074902/0001193125-19-074902-index.htm
2019-03-14	S-8	Securities to be offered to employees in employee benefit plans	https://www.sec.gov/Archives/edgar/data/1701108/000119312519074912/0001193125-19-074912-index.htm
2019-03-19	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1701108/000119312519078993/0001193125-19-078993-index.htm
2019-03-29	8-K/A	Current report	https://www.sec.gov/Archives/edgar/data/1701108/000119312519092830/0001193125-19-092830-index.htm
2019-04-18	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1701108/000119312519111025/0001193125-19-111025-index.htm
2019-04-26	DEF 14A	Other definitive proxy statements	https://www.sec.gov/Archives/edgar/data/1701108/000119312519122422/0001193125-19-122422-index.htm
2019-05-09	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1701108/000119312519142982/0001193125-19-142982-index.htm
2019-06-06	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1701108/000119312519167255/0001193125-19-167255-index.htm
2019-06-13	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1701108/000119312519171876/0001193125-19-171876-index.htm
2019-06-14	424B5	Prospectus [Rule 424(b)(5)]	https://www.sec.gov/Archives/edgar/data/1701108/000119312519172777/0001193125-19-172777-index.htm
2019-08-08	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1701108/000119312519216834/0001193125-19-216834-index.htm
2019-09-06	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1701108/000119312519239450/0001193125-19-239450-index.htm
2019-10-03	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1701108/000119312519261358/0001193125-19-261358-index.htm
2019-11-04	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1701108/000119312519283355/0001193125-19-283355-index.htm
2019-12-05	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1701108/000119312519306821/0001193125-19-306821-index.htm
2019-12-19	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1701108/000119312519319256/0001193125-19-319256-index.htm
2020-01-30	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1701108/000119312520019086/0001193125-20-019086-index.htm
2020-01-31	SC 13G/A	Statement of acquisition of beneficial ownership by individuals	https://www.sec.gov/Archives/edgar/data/1701108/000119312520021361/0001193125-20-021361-index.htm
2020-02-11	424B5	Prospectus [Rule 424(b)(5)]	https://www.sec.gov/Archives/edgar/data/1701108/000119312520030568/0001193125-20-030568-index.htm
2020-02-11	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1701108/000119312520030705/0001193125-20-030705-index.htm
2020-02-28	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1701108/000119312520056529/0001193125-20-056529-index.htm
2020-03-16	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1701108/000119312520073981/0001193125-20-073981-index.htm
2020-03-19	S-8	Securities to be offered to employees in employee benefit plans	https://www.sec.gov/Archives/edgar/data/1701108/000119312520079102/0001193125-20-079102-index.htm
2020-04-16	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1701108/000119312520108749/0001193125-20-108749-index.htm
2020-05-08	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1701108/000119312520137009/0001193125-20-137009-index.htm
2020-05-11	8-K/A	Current report	https://www.sec.gov/Archives/edgar/data/1701108/000119312520139200/0001193125-20-139200-index.htm
2020-06-04	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1701108/000119312520160206/0001193125-20-160206-index.htm
2020-08-06	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1701108/000119312520211931/0001193125-20-211931-index.htm
2020-08-06	S-8	Securities to be offered to employees in employee benefit plans	https://www.sec.gov/Archives/edgar/data/1701108/000119312520211997/0001193125-20-211997-index.htm
2020-09-08	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1701108/000119312520240546/0001193125-20-240546-index.htm
2020-09-09	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1701108/000119312520242243/0001193125-20-242243-index.htm
2020-09-09	424B5	Prospectus [Rule 424(b)(5)]	https://www.sec.gov/Archives/edgar/data/1701108/000119312520242277/0001193125-20-242277-index.htm
2020-09-14	424B5	Prospectus [Rule 424(b)(5)]	https://www.sec.gov/Archives/edgar/data/1701108/000119312520244773/0001193125-20-244773-index.htm
2020-09-14	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1701108/000119312520244804/0001193125-20-244804-index.htm
2020-09-16	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1701108/000119312520246775/0001193125-20-246775-index.htm
2020-09-30	DEF 14A	Other definitive proxy statements	https://www.sec.gov/Archives/edgar/data/1701108/000119312520259653/0001193125-20-259653-index.htm
2020-10-28	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1701108/000119312520279790/0001193125-20-279790-index.htm
2020-11-05	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1701108/000119312520286841/0001193125-20-286841-index.htm
2020-02-18	SC 13G/A	Statement of acquisition of beneficial ownership by individuals	https://www.sec.gov/Archives/edgar/data/1701108/000119380520000223/0001193805-20-000223-index.htm
2020-06-29	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1701108/000120919120039352/0001209191-20-039352-index.htm
2020-02-14	SC 13D/A	General statement of acquisition of beneficial ownership	https://www.sec.gov/Archives/edgar/data/1701108/000138713120001836/0001387131-20-001836-index.htm
2020-06-04	SC 13D/A	General statement of acquisition of beneficial ownership	https://www.sec.gov/Archives/edgar/data/1701108/000138713120005474/0001387131-20-005474-index.htm
2018-05-10	10-Q	Quarterly report [Sections 13 or 15(d)]	https://www.sec.gov/Archives/edgar/data/1701108/000156459018012933/0001564590-18-012933-index.htm
2018-08-09	10-Q	Quarterly report [Sections 13 or 15(d)]	https://www.sec.gov/Archives/edgar/data/1701108/000156459018021018/0001564590-18-021018-index.htm
2018-11-08	10-Q	Quarterly report [Sections 13 or 15(d)]	https://www.sec.gov/Archives/edgar/data/1701108/000156459018028526/0001564590-18-028526-index.htm
2019-03-14	10-K	Annual report [Section 13 and 15(d), not S-K Item 405]	https://www.sec.gov/Archives/edgar/data/1701108/000156459019007805/0001564590-19-007805-index.htm
2019-05-09	10-Q	Quarterly report [Sections 13 or 15(d)]	https://www.sec.gov/Archives/edgar/data/1701108/000156459019017941/0001564590-19-017941-index.htm
2019-08-08	10-Q	Quarterly report [Sections 13 or 15(d)]	https://www.sec.gov/Archives/edgar/data/1701108/000156459019030746/0001564590-19-030746-index.htm
2019-11-04	10-Q	Quarterly report [Sections 13 or 15(d)]	https://www.sec.gov/Archives/edgar/data/1701108/000156459019039770/0001564590-19-039770-index.htm
2020-03-16	10-K	Annual report [Section 13 and 15(d), not S-K Item 405]	https://www.sec.gov/Archives/edgar/data/1701108/000156459020010998/0001564590-20-010998-index.htm
2020-05-08	10-Q	Quarterly report [Sections 13 or 15(d)]	https://www.sec.gov/Archives/edgar/data/1701108/000156459020023243/0001564590-20-023243-index.htm
2020-08-06	10-Q	Quarterly report [Sections 13 or 15(d)]	https://www.sec.gov/Archives/edgar/data/1701108/000156459020037710/0001564590-20-037710-index.htm
2020-11-05	10-Q	Quarterly report [Sections 13 or 15(d)]	https://www.sec.gov/Archives/edgar/data/1701108/000156459020051279/0001564590-20-051279-index.htm
2019-02-14	SC 13G/A	Statement of acquisition of beneficial ownership by individuals	https://www.sec.gov/Archives/edgar/data/1701108/000159198619000004/0001591986-19-000004-index.htm
2020-02-14	SC 13G/A	Statement of acquisition of beneficial ownership by individuals	https://www.sec.gov/Archives/edgar/data/1701108/000159198620000005/0001591986-20-000005-index.htm
2020-09-22	3	Initial statement of beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1701108/000159198620000013/0001591986-20-000013-index.htm
2020-09-23	SC 13G/A	Statement of acquisition of beneficial ownership by individuals	https://www.sec.gov/Archives/edgar/data/1701108/000159198620000014/0001591986-20-000014-index.htm
2020-11-06	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1701108/000159198620000015/0001591986-20-000015-index.htm
2018-07-12	EFFECT	Notice of Effectiveness	https://www.sec.gov/Archives/edgar/data/1701108/999999999518001785/9999999995-18-001785-index.htm
2018-12-11	EFFECT	Notice of Effectiveness	https://www.sec.gov/Archives/edgar/data/1701108/999999999518003105/9999999995-18-003105-index.htm
2018-12-11	CT ORDER	Confidential treatment order	https://www.sec.gov/Archives/edgar/data/1701108/999999999718009412/9999999997-18-009412-index.htm
2019-04-01	CT ORDER	Confidential treatment order	https://www.sec.gov/Archives/edgar/data/1701108/999999999719002232/9999999997-19-002232-index.htm

Spero Therapeutics, Inc (SPRO) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Spero Therapeutics, Inc (SPRO). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 1081%
Institutional Ownership: 6098%

Transaction Date	Insider Name	Insider Title	Type	Shares Number	Shares Price	Total Transaction	Shares Held After Transaction	Link
2018-07-05	Cristina Larkin	Chief Operating Officer	Sell	4,000.00	17.50	70,000.00	1,500.00	https://www.sec.gov/Archives/edgar/data/1701108/000089924318019568/0000899243-18-019568-index.htm
2018-07-05	Joel Sendek	Chief Financial Officer	Sell	2,000.00	17.50	35,000.00	15,181.00	https://www.sec.gov/Archives/edgar/data/1701108/000089924318019567/0000899243-18-019567-index.htm
2018-07-05	Joel Sendek	Chief Financial Officer	Buy	2,000.00	5.90	11,800.00	17,181.00	https://www.sec.gov/Archives/edgar/data/1701108/000089924318019567/0000899243-18-019567-index.htm
2018-07-17	PLC GLAXOSMITHKLINE	10% Share Holder	Buy	80,000.00	12.50	1,000,000.00	1,934,006.00	https://www.sec.gov/Archives/edgar/data/1701108/000090342318000400/0000903423-18-000400-index.htm
2020-11-06	Aquilo Capital Management, LLC	10% Share Holder	Sell	5,000.00	13.77	68,873.50	4,323,042.00	https://www.sec.gov/Archives/edgar/data/1701108/000159198620000015/0001591986-20-000015-index.htm
2020-11-05	Aquilo Capital Management, LLC	10% Share Holder	Sell	96,600.00	13.98	1,350,332.76	4,328,042.00	https://www.sec.gov/Archives/edgar/data/1701108/000159198620000015/0001591986-20-000015-index.htm
2020-11-04	Aquilo Capital Management, LLC	10% Share Holder	Sell	72,500.00	14.26	1,033,741.25	4,424,642.00	https://www.sec.gov/Archives/edgar/data/1701108/000159198620000015/0001591986-20-000015-index.htm
2018-07-05	Cristina Larkin	Chief Operating Officer	Buy	4,000.00	5.90	23,600.00	5,500.00	https://www.sec.gov/Archives/edgar/data/1701108/000089924318019568/0000899243-18-019568-index.htm
2018-07-05	Ankit Mahadevia	Officer	Sell	3,076.00	17.62	54,203.73	65,817.00	https://www.sec.gov/Archives/edgar/data/1701108/000089924318019566/0000899243-18-019566-index.htm
2018-07-06	Ankit Mahadevia	Officer	Sell	200.00	17.92	3,584.00	65,817.00	https://www.sec.gov/Archives/edgar/data/1701108/000089924318019566/0000899243-18-019566-index.htm
2020-06-22	Ankit Mahadevia	CEO and President	Sell	2,613.00	14.30	37,364.85	65,817.00	https://www.sec.gov/Archives/edgar/data/1701108/000120919120039352/0001209191-20-039352-index.htm
2020-06-23	Ankit Mahadevia	CEO and President	Sell	8,045.00	14.33	115,263.93	65,817.00	https://www.sec.gov/Archives/edgar/data/1701108/000120919120039352/0001209191-20-039352-index.htm
2020-06-24	Ankit Mahadevia	CEO and President	Sell	3,880.00	14.28	55,419.59	65,817.00	https://www.sec.gov/Archives/edgar/data/1701108/000120919120039352/0001209191-20-039352-index.htm
2020-06-25	Ankit Mahadevia	CEO and President	Sell	2,642.00	14.25	37,650.35	65,817.00	https://www.sec.gov/Archives/edgar/data/1701108/000120919120039352/0001209191-20-039352-index.htm
2020-07-07	Ankit Mahadevia	CEO and President	Sell	754.00	14.25	10,744.95	65,817.00	https://www.sec.gov/Archives/edgar/data/1701108/000089924320018847/0000899243-20-018847-index.htm
2020-07-09	Ankit Mahadevia	CEO and President	Sell	2,293.00	14.31	32,806.64	65,817.00	https://www.sec.gov/Archives/edgar/data/1701108/000089924320018847/0000899243-20-018847-index.htm
2020-09-08	Ankit Mahadevia	CEO and President	Sell	774.00	14.25	11,029.73	65,817.00	https://www.sec.gov/Archives/edgar/data/1701108/000089924320024865/0000899243-20-024865-index.htm
2020-10-13	Ankit Mahadevia	CEO and President	Sell	14,367.00	14.28	205,212.48	65,817.00	https://www.sec.gov/Archives/edgar/data/1701108/000089924320028430/0000899243-20-028430-index.htm
2020-10-14	Ankit Mahadevia	CEO and President	Sell	105.00	14.25	1,496.25	65,817.00	https://www.sec.gov/Archives/edgar/data/1701108/000089924320028430/0000899243-20-028430-index.htm
2020-10-23	Ankit Mahadevia	CEO and President	Sell	20.00	14.25	285.00	65,817.00	https://www.sec.gov/Archives/edgar/data/1701108/000089924320029328/0000899243-20-029328-index.htm
2020-11-03	Ankit Mahadevia	CEO and President	Sell	2,137.00	14.27	30,489.65	65,817.00	https://www.sec.gov/Archives/edgar/data/1701108/000089924320030490/0000899243-20-030490-index.htm
2020-11-04	Ankit Mahadevia	CEO and President	Sell	7,370.00	14.43	106,335.10	65,817.00	https://www.sec.gov/Archives/edgar/data/1701108/000089924320030490/0000899243-20-030490-index.htm
2020-10-23	Ankit Mahadevia	CEO and President	Buy	20.00	5.90	118.00	65,837.00	https://www.sec.gov/Archives/edgar/data/1701108/000089924320029328/0000899243-20-029328-index.htm
2020-10-14	Ankit Mahadevia	CEO and President	Buy	105.00	5.90	619.50	65,922.00	https://www.sec.gov/Archives/edgar/data/1701108/000089924320028430/0000899243-20-028430-index.htm
2018-07-06	Ankit Mahadevia	Officer	Sell	200.00	17.90	3,580.00	66,017.00	https://www.sec.gov/Archives/edgar/data/1701108/000089924318019566/0000899243-18-019566-index.htm
2018-07-06	Ankit Mahadevia	Officer	Sell	100.00	17.71	1,770.50	66,217.00	https://www.sec.gov/Archives/edgar/data/1701108/000089924318019566/0000899243-18-019566-index.htm
2018-07-06	Ankit Mahadevia	Officer	Sell	100.00	17.62	1,762.00	66,317.00	https://www.sec.gov/Archives/edgar/data/1701108/000089924318019566/0000899243-18-019566-index.htm
2018-07-06	Ankit Mahadevia	Officer	Sell	400.00	17.58	7,032.00	66,417.00	https://www.sec.gov/Archives/edgar/data/1701108/000089924318019566/0000899243-18-019566-index.htm
2020-07-07	Ankit Mahadevia	CEO and President	Buy	754.00	5.90	4,448.60	66,571.00	https://www.sec.gov/Archives/edgar/data/1701108/000089924320018847/0000899243-20-018847-index.htm
2020-09-08	Ankit Mahadevia	CEO and President	Buy	774.00	5.90	4,566.60	66,591.00	https://www.sec.gov/Archives/edgar/data/1701108/000089924320024865/0000899243-20-024865-index.htm
2018-07-06	Ankit Mahadevia	Officer	Sell	100.00	17.55	1,754.50	66,817.00	https://www.sec.gov/Archives/edgar/data/1701108/000089924318019566/0000899243-18-019566-index.htm
2018-07-06	Ankit Mahadevia	Officer	Sell	500.00	17.50	8,750.00	66,917.00	https://www.sec.gov/Archives/edgar/data/1701108/000089924318019566/0000899243-18-019566-index.htm
2018-07-06	Ankit Mahadevia	Officer	Buy	1,600.00	5.90	9,440.00	67,417.00	https://www.sec.gov/Archives/edgar/data/1701108/000089924318019566/0000899243-18-019566-index.htm
2020-11-03	Ankit Mahadevia	CEO and President	Buy	2,137.00	5.90	12,608.30	67,954.00	https://www.sec.gov/Archives/edgar/data/1701108/000089924320030490/0000899243-20-030490-index.htm
2020-07-09	Ankit Mahadevia	CEO and President	Buy	2,293.00	5.90	13,528.70	68,110.00	https://www.sec.gov/Archives/edgar/data/1701108/000089924320018847/0000899243-20-018847-index.htm
2020-06-22	Ankit Mahadevia	CEO and President	Buy	2,613.00	5.90	15,416.70	68,430.00	https://www.sec.gov/Archives/edgar/data/1701108/000120919120039352/0001209191-20-039352-index.htm
2020-06-25	Ankit Mahadevia	CEO and President	Buy	2,642.00	5.90	15,587.80	68,459.00	https://www.sec.gov/Archives/edgar/data/1701108/000120919120039352/0001209191-20-039352-index.htm
2018-07-05	Ankit Mahadevia	Officer	Buy	3,076.00	5.90	18,148.40	68,893.00	https://www.sec.gov/Archives/edgar/data/1701108/000089924318019566/0000899243-18-019566-index.htm
2020-06-24	Ankit Mahadevia	CEO and President	Buy	3,880.00	5.90	22,892.00	69,697.00	https://www.sec.gov/Archives/edgar/data/1701108/000120919120039352/0001209191-20-039352-index.htm
2020-11-04	Ankit Mahadevia	CEO and President	Buy	7,370.00	5.90	43,483.00	73,187.00	https://www.sec.gov/Archives/edgar/data/1701108/000089924320030490/0000899243-20-030490-index.htm
2020-06-23	Ankit Mahadevia	CEO and President	Buy	8,045.00	5.90	47,465.50	73,862.00	https://www.sec.gov/Archives/edgar/data/1701108/000120919120039352/0001209191-20-039352-index.htm
2020-10-13	Ankit Mahadevia	CEO and President	Buy	14,367.00	5.90	84,765.30	80,184.00	https://www.sec.gov/Archives/edgar/data/1701108/000089924320028430/0000899243-20-028430-index.htm

Spero Therapeutics, Inc

(NASDAQ:SPRO)